Design of manganese ion coated Prussian blue nanocarrier for the therapy of refractory diffuse large B-cell lymphoma based on a comprehensive analysis of ferroptosis regulators from clinical cases

[1]  K. Cai,et al.  Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma. , 2022, Biomaterials.

[2]  L. Zhuang,et al.  Targeting ferroptosis as a vulnerability in cancer , 2022, Nature Reviews Cancer.

[3]  Jun Chen,et al.  Ferroptosis in cancer and cancer immunotherapy , 2022, Cancer communications.

[4]  R. Deng,et al.  PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis , 2022, Nature Cell Biology.

[5]  K. Fu,et al.  APR-246 Reveals a Therapeutic Potential Via Triggering Different Cell Death Mechanisms in Diffuse Large B Cell Lymphoma , 2021, Blood.

[6]  B. Stockwell,et al.  Characterization of a patient-derived variant of GPX4 for precision therapy , 2021, Nature Chemical Biology.

[7]  R. Kiyamova,et al.  61P Characterization of EMC2 gene as a potential prognostic marker of tumor diseases , 2021, Annals of Oncology.

[8]  Xiaoqiong Gu,et al.  MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma , 2021, Cell Death & Disease.

[9]  A. Rosenwald,et al.  Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL. , 2021, Blood.

[10]  A. Shah,et al.  Genetic deletion of Nox4 enhances cancerogen-induced formation of solid tumors , 2021, Proceedings of the National Academy of Sciences.

[11]  G. Kroemer,et al.  Broadening horizons: the role of ferroptosis in cancer , 2021, Nature Reviews Clinical Oncology.

[12]  Zuguo Liu,et al.  Ferroptosis drives photoreceptor degeneration in mice with defects in all-trans-retinal clearance , 2020, The Journal of biological chemistry.

[13]  P. Negredo,et al.  Protective role of microglial HO-1 blockade in aging: Implication of iron metabolism , 2020, Redox biology.

[14]  M. Conrad,et al.  The Metabolic Underpinnings of Ferroptosis. , 2020, Cell metabolism.

[15]  D. Klionsky,et al.  Ferroptosis: machinery and regulation , 2020, Autophagy.

[16]  S. Morrison,et al.  Lymph protects metastasizing melanoma cells from ferroptosis , 2020, Nature.

[17]  Zhixiang Zuo,et al.  Systematic Analysis of the Aberrances and Functional Implications of Ferroptosis in Cancer , 2020, iScience.

[18]  Jun Fang,et al.  Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. , 2020, Advanced drug delivery reviews.

[19]  M. Busquets,et al.  Prussian blue nanoparticles: synthesis, surface modification, and biomedical applications. , 2020, Drug discovery today.

[20]  Yamil D. Mahmoud,et al.  Bioinformatic profiling of tumor immunity from patient biopsies to predict survival and response to immunotherapy. , 2020 .

[21]  Yueqing Gu,et al.  Enhanced Ferroptosis by Oxygen-Boosted Phototherapy Based on 2-in-1 Nanoplatform of Ferrous Hemoglobin for Tumor Synergistic Therapy. , 2020, ACS nano.

[22]  B. Liu,et al.  PB@PDA@Ag nanosystem for synergistically eradicating MRSA and accelerating diabetic wound healing assisted with laser irradiation. , 2020, Biomaterials.

[23]  J. Cerhan,et al.  Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL , 2020, Leukemia.

[24]  Bei Sun,et al.  Ferroptosis: past, present and future , 2020, Cell Death & Disease.

[25]  Nan Zhou,et al.  FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations , 2020, Database J. Biol. Databases Curation.

[26]  Marcus Conrad,et al.  The chemical basis of ferroptosis , 2019, Nature Chemical Biology.

[27]  L. Gordon,et al.  Bio-Inspired Functional Lipoprotein-like Nanoparticles (Flip-NPs) Cause Cholesterol Starvation and Ferroptosis in B-Cell Lymphomas: Studies in Cell Lines, Xenograft Models and Primary Patient Samples , 2019, Blood.

[28]  Edward W. Tate,et al.  FSP1 is a glutathione-independent ferroptosis suppressor , 2019, Nature.

[29]  Wen-jun Wang,et al.  Manganese-based Nanoplatform as Metal Ion-Enhanced ROS Generator for Combined Chemodynamic/Photodynamic Therapy. , 2019, ACS applied materials & interfaces.

[30]  J. Olzmann,et al.  The CoQ oxidoreductase FSP1 acts in parallel to GPX4 to inhibit ferroptosis , 2019, Nature.

[31]  K. Young,et al.  Genetic alterations and their clinical implications in DLBCL , 2019, Nature Reviews Clinical Oncology.

[32]  L. Staudt,et al.  A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) , 2018, Blood.

[33]  A. Karyakin,et al.  Catalytically Synthesized Prussian Blue Nanoparticles Defeating Natural Enzyme Peroxidase. , 2018, Journal of the American Chemical Society.

[34]  N. Gu,et al.  Progress in Applications of Prussian Blue Nanoparticles in Biomedicine , 2018, Advanced healthcare materials.

[35]  F. Jardin,et al.  Novel molecular classifications of DLBCL , 2018, Nature Reviews Clinical Oncology.

[36]  S. Dong,et al.  Prussian blue with intrinsic heme-like structure as peroxidase mimic , 2018, Nano Research.

[37]  Juan Li,et al.  Simultaneous Fenton-like Ion Delivery and Glutathione Depletion by MnO2 -Based Nanoagent to Enhance Chemodynamic Therapy. , 2018, Angewandte Chemie.

[38]  Roland Schmitz,et al.  Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.

[39]  Niko Beerenwinkel,et al.  Bioinformatics for precision oncology , 2017, Briefings Bioinform..

[40]  B. Stockwell,et al.  Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease , 2017, Cell.

[41]  Yu Chen,et al.  Tumor-selective catalytic nanomedicine by nanocatalyst delivery , 2017, Nature Communications.

[42]  I. Willner,et al.  Mimicking Peroxidase Activities with Prussian Blue Nanoparticles and Their Cyanometalate Structural Analogues. , 2017, Nano letters.

[43]  S. Cuzzocrea,et al.  Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? , 2016, The oncologist.

[44]  A. D’Andrea,et al.  FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair. , 2016, Cell reports.

[45]  Jeffery A. Jones,et al.  A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. , 2015, Blood.

[46]  M. R. Lamprecht,et al.  Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.

[47]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[48]  Dianne Ford,et al.  Metalloproteins and metal sensing , 2009, Nature.

[49]  K. D'Herde,et al.  Ferroptosis: Oxidized PEs trigger death. , 2017, Nature chemical biology.

[50]  Jeffery A. Jones,et al.  A phase 1 / 1 b study of rituximab , bendamustine , and ibrutinib in patients with untreated and relapsed / refractory non-Hodgkin lymphoma , 2014 .

[51]  R. Eldik,et al.  Metal ion-catalyzed oxidative degradation of Orange II by H2O2. High catalytic activity of simple manganese salts , 2009 .